Pulseflow Logo -min

With lead investment from ‘master investor’ Jim Mellon, The Diabetic Boot Company (now Pulse Flow Technologies) successfully raised £1,764,493 to help support the company’s product development and rollout.

The story

Every 20 seconds, someone in the world loses a limb to diabetes. Studies show that 50% of those people die within 2 years. Between 2010 - 2011, the NHS spent up to £662 million on ulceration and amputation. The International Diabetes Federation forecasts that the number of diabetics worldwide is likely to reach 552 million by 2030.

CEO Les Lindsay, formerly VP of KCI Medical, founded The Diabetic Boot Company (now known as Pulseflow) to solve this problem using innovative biotechnology. The result was ‘pulseflow DF’ - a patented and clinically proven design capable of healing foot ulcers caused by diabetes within 12 weeks. What’s more, the Armstrong research study showed that the intermittent plantar compression feature utilised in the pulseflow DF resulted in 100% of wounds healed within 12 weeks for compliant patients.

Pulseflow Boot For Diabetics -min

Where are they now?

The Diabetic Boot Company has received numerous awards, including ‘Start Up Business’ Winner in the 2014 SEHTA Healthcare Business Awards. It was also a runner up for ‘Start Up Business’ in the 2015 Medilink UK Awards, and received a funding grant from Technology Strategy Board. The company was also discussed in the press, most notably in an article by The Telegraph.

Investment in this round was led by Jim Mellon, whose most notable investment was UraMin Inc which listed on AIM in 2005 and sold to Areva for £1.6 billion in 2007. You can read more about Jim Mellon in This Is Money, The Telegraph, The FT, FT Advisor and The Sunday Times.

See current opportunities

SeeQuestor

EIS
Transport & Logistics
Improving CCTV analysis to help solve crimes more efficiently and effectively, SeeQuestor raised funding on SyndicateRoom.

Active

Trading status

£14,065

Average investment

£872,034

Total raised

Apta Biosciences Ltd

EIS
Pharmaceuticals & Biotechnology
Game-changing technology for multi-billion dollar life sciences research, diagnostics and therapeutics markets. Read about Apta Biosciences raise here.

Active

Trading status

£9,944

Average investment

£964,550

Total raised

Weedingtech

EIS
Technology, Hardware & Equipment
Manufacturers of Europe’s leading herbicide-free weed control systems, Weedingtech raised funds on SyndicateRoom. Read about the raise here.

Active

Trading status

£19,543

Average investment

£801,257

Total raised

Bactest - Round 2

EIS
Pharmaceuticals & Biotechnology
Bactest develops and sells products based on its propriety technology platform that turns microbial activity into data.

No longer trading

Trading status

£12,070

Average investment

£301,760

Total raised

Fertility Focus - Round 2

EIS
Medtech
The only product on the market that detects ovulation with 99% accuracy, Fertility Focus raised funds on SyndicateRoom. Read about the raise here.

Active

Trading status

£10,917

Average investment

£360,250

Total raised

Enval

EIS
Engineering & Manufacturing
Enval’s microwave induced pyrolysis process is a world-first method for recycling laminated packaging, and is now operational at full commercial-scale.

Active

Trading status

£14,655

Average investment

£981,870

Total raised